Want to see SCND full AI Analyst Report?
Top Page
Scientific Industries
(OTC:SCND)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.71
▲(21.90% Upside)
Action:Reiterated
Date:07/31/26
The score is driven primarily by weak financial performance: steep revenue and margin deterioration alongside continued losses and sustained cash burn, despite a relatively low-leverage balance sheet. Technicals add modest additional pressure as the stock trades below key moving averages, while valuation is constrained by a negative P/E and no provided dividend yield.
Positive Factors
Low Leverage / Strong Balance Sheet
Relative low leverage gives the company financial flexibility to fund operations, tolerate cyclical revenue shortfalls, and pursue targeted product or channel investments without immediate refinancing. This structural balance-sheet strength reduces default risk over months.
Negative Factors
Revenue Decline & Margin Compression
A sharp revenue drop with pronounced gross-margin compression indicates structural demand weakness or worsening mix/pricing power. Persisting at these levels would erode scale economics and reduce the firm's ability to cover fixed costs, hindering sustainable profitability over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
Relative low leverage gives the company financial flexibility to fund operations, tolerate cyclical revenue shortfalls, and pursue targeted product or channel investments without immediate refinancing. This structural balance-sheet strength reduces default risk over months.
Read all positive factors
Scientific Industries (SCND) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.83M
Dividend YieldN/A
Average Volume (3M)12.23K
Price to Earnings (P/E)―
Beta (1Y)0.45
Revenue Growth-38.06%
EPS Growth85.57%
CountryUS
Employees55
SectorTechnology
Sector Strength88
IndustryHardware, Equipment & Parts
Share Statistics
EPS (TTM)-0.08
Shares Outstanding11,928,599
10 Day Avg. Volume13,652
30 Day Avg. Volume12,230
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.60
Price to Sales (P/S)1.26
P/FCF Ratio-0.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Scientific Industries Business Overview & Revenue Model
Company Description
Scientific Industries, Inc. operates as a global enterprise specializing in the development, production, and distribution of a comprehensive range of benchtop laboratory instrumentation and advanced bioprocessing systems. Their product line featur...
How the Company Makes Money
Scientific Industries makes money primarily by selling laboratory instruments and related accessories to customers in life science, clinical, academic, and industrial settings. Its core revenue stream is product sales of benchtop laboratory equipm...
Scientific Industries Earnings Call Summary
Earnings Call Date:Nov 15, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Aug 19, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant growth in the VIVID pill counter business and successful cost-cutting initiatives, alongside promising developments and strategic partnerships in the bioprocessing segment. However, challenges in the European market remain a concern.Positive Updates
VIVID Pill Counter Business Growth
VIVID sales in the third quarter were up 50% compared to the second quarter of this year and 12% compared to the same quarter last year. The development of a new VIVID workstation is expected to be a game-changer in the market.
Negative Updates
Challenging Bioprocessing Market
The bioprocessing segment faced a challenging environment with budget constraints impacting customers, particularly in Europe, leading to postponed equipment investments.
Read all updates
Q3-2024 Updates
Positive
Negative
VIVID Pill Counter Business Growth
VIVID sales in the third quarter were up 50% compared to the second quarter of this year and 12% compared to the same quarter last year. The development of a new VIVID workstation is expected to be a game-changer in the market.
Read all positive updates
Company Guidance
During the third quarter of 2024, Scientific Industries demonstrated significant progress in its strategic transformation into a life sciences tool business with notable growth in sales, margins, and recurring revenue. The legacy Genie business experienced a recovery, generating positive cash flow that supports investments in the VIVID pill counter business, which saw a 50% increase in sales compared to the previous quarter and 12% year-over-year growth. The company is excited about the upcoming launch of the VIVID workstation, a new all-in-one pill counter and pharmacy management system. In the bioprocessing segment, sales increased by 12% compared to the previous year, with a remarkable 61% year-over-year growth in the U.S. market. Efforts to improve cost efficiency resulted in a reduction of operating expenses by over $1 million, or 22%, compared to the previous year. The company also reported a positive EBITDA margin of 14% for its U.S. entity in September, marking a significant milestone. Scientific Industries continues to invest in R&D and commercial activities, with a growing commercial pipeline and the successful launch of the DOTS platform, reflecting its potential to deliver long-term shareholder value.Scientific Industries Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
15
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Jun 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.05M | 10.71M | 11.11M | 10.48M | 9.78M |
| Gross Profit | 1.30M | 4.73M | 5.10M | 4.64M | 4.98M |
| EBITDA | -7.89M | -5.89M | -8.51M | -7.41M | -4.46M |
| Net Income | -1.22M | -6.45M | -9.09M | -8.15M | -3.11M |
Balance Sheet | |||||
| Total Assets | 12.61M | 11.56M | 16.73M | 18.07M | 29.01M |
| Cash, Cash Equivalents and Short-Term Investments | 6.66M | 2.57M | 5.72M | 6.20M | 13.42M |
| Total Debt | 966.70K | 1.00M | 1.33M | 1.43M | 1.49M |
| Total Liabilities | 1.94M | 2.44M | 2.85M | 3.28M | 2.78M |
| Stockholders Equity | 10.66M | 9.12M | 13.89M | 14.79M | 26.22M |
Cash Flow | |||||
| Free Cash Flow | -8.21M | -3.78M | -6.29M | -6.20M | -3.56M |
| Operating Cash Flow | -8.15M | -3.68M | -6.16M | -5.70M | -3.30M |
| Investing Cash Flow | 3.83M | 2.87M | -735.10K | 3.61M | -10.88M |
| Financing Cash Flow | 1.95M | 645.70K | 5.75M | 2.31M | 16.31M |
Scientific Industries Technical Analysis
Positive
0.58
Price Trends
0.64
Positive
0.68
Positive
0.65
Positive
Market Momentum
>-0.01
Negative
67.43
Neutral
96.49
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCND, the sentiment is Positive. The current price of 0.58 is below the 20-day moving average (MA) of 0.60, below the 50-day MA of 0.64, and below the 200-day MA of 0.65, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 67.43 is Neutral, neither overbought nor oversold. The STOCH value of 96.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SCND.
Scientific Industries Risk Analysis
Scientific Industries disclosed 12 risk factors in its most recent earnings report. Scientific Industries reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Scientific Industries Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
49 Neutral | $59.48M | -19.83 | -6.69% | 2.13% | 4.15% | -186.73% | |
43 Neutral | $333.35M | -0.03 | -329.57% | ― | -36.42% | 94.91% | |
41 Neutral | $8.83M | -9.25 | -65.40% | ― | -38.06% | 85.57% | |
40 Underperform | $1.62M | -0.11 | -171.94% | ― | 70.99% | 97.04% |
* Technology Sector Average
SCND
Scientific Industries
0.74
-0.14
-15.91%
ELTK
Eltek
8.85
-1.43
-13.91%
IMTE
Integrated Media Technology
0.48
-0.53
-52.38%
SOBR
SOBR Safe
0.58
-2.56
-81.56%
OST
Ostin Technology Group Co., Ltd.
1.70
-0.10
-5.83%
SVRE
SaverOne 2014 Ltd. ADR
3.70
-20.18
-84.51%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.